Drug targets and predictive biomarkers in the management of metastatic melanoma

Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently, the therapeutic options for treatment of metastatic melanoma were limited. The approval of ipilimumab (an anti-CTLA-...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacogenomics and personalized medicine 2012-01, Vol.5 (default), p.139-148
Main Authors: Thumar, Jaykumar, Giesen, Eva, Kluger, Harriet M
Format: Article
Language:English
Subjects:
Biological markers
Biomarkers
Cancer
Care and treatment
Drug targeting
Identification and classification
inhibitors
Melanoma
Metastasis
Monoclonal antibodies
mutations
Review
Skin cancer
tumors
vemurafenib
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently, the therapeutic options for treatment of metastatic melanoma were limited. The approval of ipilimumab (an anti-CTLA-4 antibody) and vemurafenib (mutant B-RAF(V600E) kinase inhibitor) by the Federal Drug Administration has led to a new era in melanoma treatment, and additional promising drugs and drug combinations are currently being investigated. As the choices of treatment for melanoma have expanded, the need to identify predictive biomarkers to tailor treatment strategies to individual tumor or immune system characteristics has become necessary. Such strategies have the potential of maximizing antitumor effect while minimizing toxicity and improving clinical benefit. In this article, we review the currently approved targeted therapies in melanoma and discuss the future of personalized therapy for this disease.
ISSN:1178-7066
1178-7066
DOI:10.2147/PGPM.S25100